BreezeBio
PrivateLast Round
Series B
Feb 25, 2026
Total Funding Raised
$153.55M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
BreezeBio is a biotechnology company that develops precision genetic medicines for autoimmune diseases and oncology using its proprietary NanoGalaxy nanoparticle delivery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BreezeBio Comparables
Compare BreezeBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Code Biotherapeutics | 88% | |
| ViaNautis Bio | 84% | |
| Hopewell Therapeutics | 82% |
BreezeBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 25, 2026 | ||||
| Series B | Nov 20, 2024 | ||||
| Series A Extension | Jan 23, 2024 | ||||
| Grant | Dec 13, 2023 | ||||
| Series A | Sep 23, 2021 | ||||
Seed | Dec 11, 2018 |
Key People
Founding team and executive leadership
BreezeBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series B |
| DSC Investment | Series B |
| Top Harvest Capital | Series B |
| K2 Investment Partners | Series A Extension |
| IMM Investment | Series A, Series A Extension |
| KB Investment | Series A, Series A Extension |
| DAYLI Partners | Series A Extension, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Focus on IND-enabling studies for genetic medicine delivery platform.
- Feb 25, 2026
$60M round led by DSC Investment and Yuanta Investment.
BreezeBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BreezeBio's valuation, stock price, and market status.
Is Genedit a public or private company?
Genedit is a private company.
What is the current stock price of Genedit?
Genedit is a private company with no public stock price. No recent secondary market data is available.
How much is Genedit worth (valuation)?
Valuation information for Genedit is not publicly available.
Can I buy Genedit stock?
Genedit shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Genedit's last funding round?
Genedit's most recent funding round was Series B on November 20, 2024.
Who are the main investors in Genedit?
Key investors in Genedit include DSC Investment, DAYLI Partners, DCVC Bio, Company K Partners, IMM Investment.
Will Genedit IPO soon?
No public IPO plans have been announced for Genedit.
How can I track Genedit secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genedit's secondary market activity and sign up for updates.